Sandoz's Golden Decade: Historic GLP-1 Approval and a 36-Asset Biosimilar Engine
H1 2026 delivers strong growth, a record pipeline, and a landmark semaglutide approval — yet pricing dynamics in Germany and North America temper the story.
SDZ.SW · Earnings Call · 2026-08-05
The Golden Decade Narrative Gains Traction
Sandoz entered its fourth year as an independent company with a clear message: the biosimilar pipeline is now unmatched. On the H1 2026 call, CEO Richard Saynor highlighted the addition of four in-house assets, taking the total to 36. “We further strengthened our industry-leading biosimilar pipeline through the addition of 4 in-house assets, bringing our total biosimilar pipeline to up to 36 assets.” — Richard Saynor, Chief Executive Officer · 2026-08-05 This is a significant step up from the 29 assets disclosed a year ago, and a far cry from the 5 assets the company held five years earlier. Just a year ago, Saynor had noted: “That takes us down to 29 assets in our pipeline. 5 years ago, we had five assets.” — Richard Saynor · 2025-05-02 The pace of expansion is remarkable, underpinning what Saynor calls the "golden decade" for biosimilars.
But if you then think about the golden decade, I think it's always a little bit counterintuitive, but actually, the competitive intensity is going down, not going up.
With ~100 biologics losing exclusivity over the next decade, each with only 1-2 expected entrants, Sandoz's scale and commercial infrastructure are becoming moats. The financial results reflect this: net sales grew 5% in H1, biosimilars surged 20%, and core EBITDA margin expanded 90 basis points to 20.9%, with core diluted EPS up 17% to $1.71. The company reconfirmed full-year guidance, though it now expects price erosion to be mid-single-digit rather than low-to-mid, a subtle but meaningful shift.
GLP-1: From Ambition to First Approval
The most notable news was the approval of semaglutide in Brazil, Sandoz's first GLP-1 medicine. Saynor called it a "historic milestone" on the call. “we received regulatory approval for a new semaglutide treatment option in Brazil, paving the way to expand patient access in this important market.” — Richard Saynor, Chief Executive Officer · 2026-08-05 This was long expected — the company had filed in Canada, Brazil and other markets last year, but approvals had been pending. On the prior call, Saynor had said: “We've not guided because I guess there's so many variables at the moment. We filed in Canada, Brazil and a number of other markets with one or more partners because when we get an approval and we launch a product, we will launch it.” — Richard Saynor, CEO · 2026-02-25 Now, with Brazil approved and Canada likely later this year, the GLP 1 strategy is moving from promise to reality. The company remains cautious about the near-term contribution, but the launch plan for Brazil later this year, followed by other international markets, sets up 2027 and 2028 as the key years. As Saynor noted, "It becomes more interesting as you get into 2027." The opportunity is anchored by semaglutide, and the company's multisource strategy gives it flexibility across partners and geographies.
Pricing Pressures and Margin Resilience
Despite the positive headline, the call had a recurring undercurrent: price erosion. Management explicitly raised its 2026 expectation to mid-single-digit decline, citing near-term dynamics in Germany and North America. The German market has seen tender processes and substitution rules that pressured prices, but Remco Steenbergen emphasized that the volume response more than offsets: "We don't see any impact on nor the profitability nor the top line." The North American strength, driven by Wyost & Jubbonti and other launches, also attracts higher price erosion, but the mix remains favorable. The company's ability to expand margins while absorbing these headwinds is a testament to its International markets diversification and operating leverage. The core EBITDA margin guidance of ~100 basis points for the full year remains intact, and management sees a clear path to the 24-26% mid-term target.
The legacy litigation settlement also resolved a long-standing overhang. The $478.5 million in settlements covering U.S. state and federal claims was framed as a positive step, with no impact on guidance. This, combined with the SMI inclusion in September, reinforces the maturity of the standalone story.
Overall, Sandoz's H1 2026 was about consistency and execution. The company is not just riding the biosimilar wave; it is actively shaping it, with an expanded pipeline, a historic GLP-1 approval, and a margin trajectory that continues to beat expectations. The key risk remains pricing pressure, but management's confidence in the golden decade suggests they have the playbook to navigate it. As Saynor closed the call: "We're very confident in what Sandoz can achieve."